New-onset diabetes in COVID-19: The molecular pathogenesis

• Published in: Biomedicine (Taipei) Vol. 13; no. 1; pp. 3 - 12
• Main Authors: Wihandani, Desak Made, Purwanta, Made Lady Adelaida, Mulyani, W Riski Widya, Putra, I Wayan Ardyan Sudharta, Supadmanaba, I Gede Putu
• Format: Journal Article
• Language: English
• Published: China (Republic : 1949- ) China Medical University 2023
• Subjects: Review; COVID-19; ACE2; Diabetes; SARS coronavirus
• ISSN: 2211-8020; 2211-8039; 2211-8039
• DOI: 10.37796/2211-8039.1389

Diabetes mellitus (DM) is still a challenging metabolic disease worldwide. In the current situation, the world is facing a COVID-19 pandemic due to SARS-CoV-2 infection. DM is one of the comorbid conditions that can worsen the severity of the COVID-19 condition. Surprisingly, SARS-CoV-2 infection can induce new-onset diabetes, a condition in which acute hyperglycemia occurs and may develop into a complication in nondiabetic patients. Angiotensinconverting enzyme 2 (ACE2) is a crucial entry factor for SARS-CoV-2 infection. ACE2 will bind to the spike protein of SARS-CoV-2, potentially initiating a damaging process in many tissues in the human body, including metabolic tissues. This mechanism suggests a potential role of ACE2 in the pathogenesis of diabetes since ACE2 has been proven to localize in essential metabolic tissues, one of which is the acini and islets part of the pancreas. This interrelated ACE2 in COVID-19 and DM is thought of as the mechanism that induces new-onset diabetes in COVID-19 patients. This review will thoroughly describe the current findings and theories regarding the molecular mechanism of SARS-CoV-2-induced new-onset diabetes and the possible therapeutic intervention.